STOCK TITAN
  1. Home
  2. Sec-filings
  3. BOLT
  4. [Form 4] Bolt Biotherapeutics, Inc. Insider Trading Activity

Bolt Biotherapeutics (BOLT) reports director stock option replacement details

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Bolt Biotherapeutics, Inc. director reported stock option transactions dated 12/12/2025. The Form 4 shows several director stock options on common stock being canceled and replaced with new options that have a lower exercise price, as described in the footnotes.

New director stock options with exercise prices such as $5.44 per share cover grants expiring on 12/13/2031, 03/23/2032, 06/09/2032, 06/11/2033, 06/11/2034 and 05/26/2035. One option is fully vested and exercisable, while another for 1,100 shares will vest on the earlier of May 27, 2026 or the day immediately before the next annual meeting of stockholders, and will vest in full upon a change in control, subject to the director’s continuous service.

Positive

  • None.

Negative

  • None.
Insider ONETTO NICOLE
Role Director
Type Security Shares Price Value
Grant/Award Director Stock Option (Right to Buy) 1,393 $0.00 --
Disposition Director Stock Option (Right to Buy) 1,393 $0.00 --
Grant/Award Director Stock Option (Right to Buy) 1,107 $0.00 --
Disposition Director Stock Option (Right to Buy) 1,107 $0.00 --
Grant/Award Director Stock Option (Right to Buy) 611 $0.00 --
Disposition Director Stock Option (Right to Buy) 611 $0.00 --
Grant/Award Director Stock Option (Right to Buy) 1,250 $0.00 --
Disposition Director Stock Option (Right to Buy) 1,250 $0.00 --
Grant/Award Director Stock Option (Right to Buy) 1,250 $0.00 --
Disposition Director Stock Option (Right to Buy) 1,250 $0.00 --
Grant/Award Director Stock Option (Right to Buy) 1,100 $0.00 --
Disposition Director Stock Option (Right to Buy) 1,100 $0.00 --
Grant/Award Director Stock Option (Right to Buy) 1,100 $0.00 --
Disposition Director Stock Option (Right to Buy) 1,100 $0.00 --
Holdings After Transaction: Director Stock Option (Right to Buy) — 1,393 shares (Direct)
Footnotes (1)
  1. The option is fully vested and exercisable. The reporting person agreed to cancellation of an option granted on December 14, 2021, in exchange for a new option having a lower exercise price. The reporting person agreed to cancellation of an option granted on March 24, 2022, in exchange for a new option having a lower exercise price. The reporting person agreed to cancellation of an option granted on June 10, 2022, in exchange for a new option having a lower exercise price. The reporting person agreed to cancellation of an option granted on June 12, 2023, in exchange for a new option having a lower exercise price. The reporting person agreed to cancellation of an option granted on June 12, 2024, in exchange for a new option having a lower exercise price. The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. The reporting person agreed to cancellation of an option granted on May 27, 2025, in exchange for a new option having a lower exercise price.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ONETTO NICOLE
(Last) (First) (Middle)
C/O BOLT BIOTHERAPEUTICS, INC.
900 CHESAPEAKE DRIVE
(Street)
REDWOOD CITY CA 94063
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Bolt Biotherapeutics, Inc. [ BOLT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Director Stock Option (Right to Buy) $5.44 12/12/2025 A 1,393 (1) 12/13/2031 Common Stock 1,393 (2) 1,393 D
Director Stock Option (Right to Buy) $83.8 12/12/2025 D 1,393 (1) 12/13/2031 Common Stock 1,393 (2) 0 D
Director Stock Option (Right to Buy) $5.44 12/12/2025 A 1,107 (1) 03/23/2032 Common Stock 1,107 (3) 1,107 D
Director Stock Option (Right to Buy) $60.6 12/12/2025 D 1,107 (1) 03/23/2032 Common Stock 1,107 (3) 0 D
Director Stock Option (Right to Buy) $5.44 12/12/2025 A 611 (1) 03/23/2032 Common Stock 611 (3) 611 D
Director Stock Option (Right to Buy) $60.6 12/12/2025 D 611 (1) 03/23/2032 Common Stock 611 (3) 0 D
Director Stock Option (Right to Buy) $5.44 12/12/2025 A 1,250 (1) 06/09/2032 Common Stock 1,250 (4) 1,250 D
Director Stock Option (Right to Buy) $39.8 12/12/2025 D 1,250 (1) 06/09/2032 Common Stock 1,250 (4) 0 D
Director Stock Option (Right to Buy) $5.44 12/12/2025 A 1,250 (1) 06/11/2033 Common Stock 1,250 (5) 1,250 D
Director Stock Option (Right to Buy) $32.6 12/12/2025 D 1,250 (1) 06/11/2033 Common Stock 1,250 (5) 0 D
Director Stock Option (Right to Buy) $5.44 12/12/2025 A 1,100 (1) 06/11/2034 Common Stock 1,100 (6) 1,100 D
Director Stock Option (Right to Buy) $15.364 12/12/2025 D 1,100 (1) 06/11/2034 Common Stock 1,100 (6) 0 D
Director Stock Option (Right to Buy) $5.44 12/12/2025 A 1,100 (7) 05/26/2035 Common Stock 1,100 (8) 1,100 D
Director Stock Option (Right to Buy) $6.4 12/12/2025 D 1,100 (7) 05/26/2035 Common Stock 1,100 (8) 0 D
Explanation of Responses:
1. The option is fully vested and exercisable.
2. The reporting person agreed to cancellation of an option granted on December 14, 2021, in exchange for a new option having a lower exercise price.
3. The reporting person agreed to cancellation of an option granted on March 24, 2022, in exchange for a new option having a lower exercise price.
4. The reporting person agreed to cancellation of an option granted on June 10, 2022, in exchange for a new option having a lower exercise price.
5. The reporting person agreed to cancellation of an option granted on June 12, 2023, in exchange for a new option having a lower exercise price.
6. The reporting person agreed to cancellation of an option granted on June 12, 2024, in exchange for a new option having a lower exercise price.
7. The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.
8. The reporting person agreed to cancellation of an option granted on May 27, 2025, in exchange for a new option having a lower exercise price.
/s/ William P. Quinn, Attorney-in-Fact 12/16/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did Bolt Biotherapeutics (BOLT) report in this Form 4?

A Bolt Biotherapeutics director reported multiple transactions on 12/12/2025, canceling previously granted director stock options and receiving new options on the company’s common stock with lower exercise prices.

What type of securities are involved in the Bolt Biotherapeutics (BOLT) Form 4?

The transactions involve Director Stock Options (Right to Buy) that are exercisable for shares of Bolt Biotherapeutics common stock, with various expiration dates in 2031 through 2035.

Were any of the Bolt Biotherapeutics director options fully vested?

Yes. Footnote 1 states that one option is fully vested and exercisable, meaning the director can already exercise that particular stock option grant.

What is one example of a new exercise price reported in the Bolt Biotherapeutics Form 4?

Several replacement grants carry an exercise price of $5.44 per share for director stock options linked to Bolt Biotherapeutics common stock.

How do the vesting terms work for the new 1,100-share option at Bolt Biotherapeutics?

For the 1,100-share director option referenced in footnote 7, the shares will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the director’s continuous service, and will vest in full upon a change in control of the issuer.

Are the Bolt Biotherapeutics director options held directly or indirectly?

The table indicates the director’s derivative securities are held with direct (D) ownership, rather than through an indirect ownership structure.